Clune & Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

Clune & Associates’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$36.6K	Hold	16,500	–	–	0.01%	163
2026 Q2	$44.1K	Hold	16,500	–	–	0.01%	170
2026 Q1	$38.9K	Hold	16,500	–	–	0.01%	162
2025 Q4	$34.8K	Hold	16,500	–	–	0.01%	166
2025 Q3	$28.2K	Hold	16,500	–	–	0.01%	159
2025 Q2	$19.1K	Hold	16,500	–	–	0.01%	156
2025 Q1	$18.2K	Hold	16,500	–	–	0.01%	141
2024 Q4	$28.4K	Buy	+16,500	New	+$39.7K	0.01%	136

Other funds holding ABOS

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Clune & Associates's ABOS Position: Q3 2026 in Review

Clune & Associates held its Acumen Pharmaceuticals (ABOS) position steady in Q3 2026 at 16,500 shares worth $36.6K. The position accounts for 0.01% of the portfolio, ranked #163.

Clune & Associates first reported a position in ABOS in Q4 2024 and has held it in 8 quarters since. The position peaked at $44.1K in Q2 2026. 3 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Clune & Associates held 16,500 shares of Acumen Pharmaceuticals worth $36.6K as of Q3 2026.
Clune & Associates left its Acumen Pharmaceuticals share count unchanged in Q3 2026.
Acumen Pharmaceuticals made up 0.01% of Clune & Associates's portfolio in Q3 2026, its #163 holding.
Clune & Associates first reported a position in Acumen Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Clune & Associates's Acumen Pharmaceuticals position peaked at $44.1K in Q2 2026.
3 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Clune & Associates's 13F filing for Q3 2026, filed 8 Oct 2026.